Skip to main content

MAP3K7 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 2 bp insertion in exon 6.

Be the first to review this product! Submit a review

Images

Western blot - Human MAP3K7 (TAK1) knockout HEK-293T cell lysate (AB256984), expandable thumbnail
  • Sanger Sequencing - Human MAP3K7 (TAK1) knockout HEK-293T cell lysate (AB256984), expandable thumbnail

Key facts

Cell type
HEK-293T
Species or organism
Human
Tissue
Kidney
Knockout validation
Sanger Sequencing, Western blot
Mutation description
Knockout achieved by using CRISPR/Cas9, Homozygous: 2 bp insertion in exon 6.

Alternative names

What's included?

1 Kit
Components
Human MAP3K7 knockout HEK293T cell lysate
1 x 100 µg
Human wild-type HEK293T cell lysate
1 x 100 µg

Recommended products

MAP3K7 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 2 bp insertion in exon 6.

Key facts

Cell type
HEK-293T
Mutation description
Knockout achieved by using CRISPR/Cas9, Homozygous: 2 bp insertion in exon 6.
Concentration
Loading...

Properties

Gene name
MAP3K7
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot
Zygosity
Homozygous

Quality control

STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level
EU: 2 US: 2
Adherent/suspension
Adherent
Gender
Female

Storage

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Notes


Knockout cell lysate achieved by CRISPR/Cas9.

Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

TAK1 also known as MAP3K7 (Mitogen-activated protein kinase kinase kinase 7) is an important protein kinase that weighs approximately 63 kDa. This protein is expressed in various tissues and cells including HEK 293T cells. TAK1 plays a mechanical role as a part of the MAPK signaling cascade. It phosphorylates and activates downstream kinases which is key to transmitting cellular signals that regulate responses to external stimuli like cytokines and stress.

Biological function summary

TAK1 is involved in several cellular processes necessary for maintaining balance and responding to stress. TAK1 forms a complex with proteins like TAB1 TAB2 and TAB3 which are important for its activation and signaling function. This complex facilitates TAK1's involvement in inflammation and immune response indicating its significance in mediating cellular survival and apoptosis.

Pathways

TAK1 operates within the NF-κB and MAPK pathways two critical routes for cellular response to inflammation and stress. In the NF-κB pathway TAK1 activates IKK which triggers the degradation of IκB freeing NF-κB to move into the nucleus and activate transcription. In the MAPK pathway TAK1 directly influences JNK and p38 cascades revealing regulatory connections to proteins like MEK and ERK.

Associated diseases and disorders

TAK1 has been linked to conditions such as cancer and inflammatory diseases. In cancers aberrant TAK1 activity can lead to enhanced cell proliferation and survival. Moreover inflammation-related disorders can arise from malfunctioning TAK1 signaling demonstrating its connection to proteins like TNF receptor-associated factors which are involved in inflammatory responses. Understanding TAK1's role in these disorders may pave the way for developing potential therapeutic interventions.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

2 product images

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com